Analysis Xvivo Perfusion AB (XVIPF)
6/5/2024
Analysis of Xvivo Perfusion AB (XVIPF)
Xvivo Perfusion AB (XVIPF) has shown a consistent increase in price over the past few days. The Relative Strength Index (RSI) is indicating overbought conditions, with values above 70, suggesting a possible reversal or correction in the near future.The Moving Average Convergence Divergence (MACD) indicator is positive, with the MACD line above the signal line, indicating bullish momentum. However, the MACD histogram is decreasing, which could signal a potential weakening of the bullish trend.
In terms of moving averages, the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all showing an upward trend, indicating positive price momentum.
Overall, while the stock has been performing well recently, traders should be cautious of the overbought conditions and potential signs of a weakening bullish trend indicated by the MACD histogram.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's same quarter. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates increases to 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the analysts are forecasting moderate to strong sales growth for both the upcoming quarters and the next fiscal year, with an increasing number of analysts providing estimates for the company's performance.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.6%
- The next quarter growth rate is 5.1%
- The current quarter growth rate is 5.1%
- The next year growth rate is 9.7%
- The average annual growth rate for the next 5 years is 9.7%
- The average annual growth rate for the past 5 years is 20.1%
It can be observed that the company is expected to experience a significant increase in growth compared to the past 5 years, with a particularly strong growth forecast for the next year and the next 5 years. The growth rates for the current and next quarter are more moderate in comparison.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range of predictions, from a low of $164 to a high of $275, indicating some uncertainty in the market.
Earnings
The company's results for the quarter ending April 30, 2025, have not been provided at this time. The results for the quarter ending February 27, 2025, are with the Transfer Agent. The results for the quarter ending January 31, 2025, were reported after hours. The results for the quarter ending October 31, 2024, have not been provided at this time. The results for the quarter ending August 1, 2024, showed an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.43.
Moving on to stock statistics, the company has a short ratio of 1.53, with 15.31 billion float shares and 99.29 million shares shorted. The stock has 15.33 billion shares outstanding, with 5.22% held by insiders and 57.59% held by institutions.
Valuation metrics show a PEG ratio of 26.32, forward PE of 26.32, and trailing PE of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65. The company's market capitalization is $2.92 trillion.
The stock price summary includes a beta of 1.264, 50-day moving average of $176.26, 200-day moving average of $181.04, and a 52-week range from $164.08 to $199.62.
Lastly, dividends and splits information shows a payout ratio of 14.93%, with a dividend date on May 16, 2024. The last split date was on August 31, 2020, with a 4-for-1 split factor. The forward annual dividend rate is $1, with a 5-year average dividend yield of 0.73% and a trailing annual dividend yield of 0.51%.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023, indicating overall profitability growth.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy EBITDA margin, indicating strong operational performance.
8. The company's effective tax rate has remained relatively stable over the years.
9. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been increasing over the years, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS):1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is also an increase from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a potential increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, showing growth in both the quarterly and annual results over the specified periods.
MACD of XVIPF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
